Morris A. Blajchman

Morris A. Blajchman's AcademicInfluence.com Rankings

Morris A. Blajchman

Philosophy

#6394

World Rank

#9427

Historical Rank

Logic

#3569

World Rank

#4755

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Morris A. Blajchman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Morris A. Blajchman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. (1999) (4305)
A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. (2008) (1070)
Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? (2001) (610)
Transfusion-related immunomodulation (TRIM): an update. (2007) (582)
Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. (2009) (558)
Age of transfused blood in critically ill adults. (2015) (508)
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? (2001) (417)
The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. (2006) (404)
Effects of red-cell storage duration on patients undergoing cardiac surgery. (2015) (402)
Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. (2012) (400)
Histocompatibility (HL-A) Antigens, Lymphocytotoxic Antibodies and Tissue Antibodies in Patients with Diabetes Mellitus (1973) (397)
Proceedings of a consensus conference: towards an understanding of TRALI. (2005) (373)
Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. (2003) (367)
Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. (1997) (345)
Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. (2003) (263)
Inhibition of Injury Induced Thromboatherosclerotic Lesions by Anti-Platelet Serum in Rabbits (1976) (242)
Biologic effects of leukocytes present in transfused cellular blood products (1994) (231)
Blood product-associated bacterial sepsis. (1991) (231)
A Canadian survey of transfusion practices in critically ill patients. Transfusion Requirements in Critical Care Investigators and the Canadian Critical Care Trials Group. (1998) (186)
A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets (2002) (186)
Immunomodulation and Blood Transfusion (2002) (179)
Blood Still Kills: Six Strategies to Further Reduce Allogeneic Blood Transfusion-Related Mortality (2010) (171)
Bacterial detection of platelets: current problems and possible resolutions. (2005) (168)
Allogeneic blood transfusions, immunomodulation, and postoperative bacterial infection: Do we have the answers yet? (1997) (165)
Transfusion requirements in critical care : a pilot study (1995) (157)
Improving the bacteriological safety of platelet transfusions. (2004) (154)
Do blood transfusions improve outcomes related to mechanical ventilation? (2001) (153)
The Age of Blood Evaluation (ABLE) randomized controlled trial: study design. (2011) (146)
Clinical review: Canadian National Advisory Committee on Blood and Blood Products - Massive Transfusion Consensus Conference 2011: report of the panel (2011) (138)
The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. (1987) (135)
Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. (1992) (133)
Antithrombin III Mutation Database: First Update (1993) (131)
Universal WBC reduction:the case for and against (2001) (127)
Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A (2000) (123)
Variation in red cell transfusion practice in the intensive care unit: a multicentre cohort study (1999) (121)
Rifampicin-induced Immune Thrombocytopenia (1970) (118)
The continuing risk of transfusion-transmitted infections. (2006) (116)
Effects of Unfractionated Heparin, Dermatan Sulfate and Low Molecular Weight Heparin on Vessel Wall Permeability in Rabbits a (1989) (115)
The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals (1994) (109)
Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants. (2003) (109)
Neurodevelopmental Outcome of Extremely Low Birth Weight Infants Randomly Assigned to Restrictive or Liberal Hemoglobin Thresholds for Blood Transfusion (2009) (108)
Hemostatic function, survival, and membrane glycoprotein changes in young versus old rabbit platelets. (1981) (104)
Shortening of the bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the vessel wall. (1979) (103)
Proceedings of a Consensus Conference: Pathogen Inactivation—Making Decisions About New Technologies☆ (2007) (102)
Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. (1984) (101)
The clinical benefits of the leukoreduction of blood products. (2006) (98)
Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. (1989) (97)
BACTERIAL CONTAMINATION OF CELLULAR BLOOD COMPONENTS (1994) (97)
Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. (2010) (96)
Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. (2009) (94)
Transfusion requirements in critical care. A pilot study. Canadian Critical Care Trials Group. (1995) (92)
Allogeneic Blood Transfusion-Induced Enhancement of Tumor Growth: Two Animal Models Showing Amelioration by Leukodepletion and Passive Transfer Using Spleen Cells (1993) (92)
New strategies for the optimal use of platelet transfusions. (2008) (92)
Transfusion immunomodulation or TRIM: What does it mean clinically? (2005) (91)
Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. (1993) (91)
Prevalence of antithrombin deficiency in healthy blood donors: A cross‐sectional study (1994) (90)
Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests (1995) (89)
An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion. (1992) (88)
Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. (2001) (87)
Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity. (1988) (84)
Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion. (1994) (82)
REVIEW OF THE CLINICAL PRACTICE LITERATURE ON ALLOGENEIC RED BLOOD CELL TRANSFUSION (1997) (81)
Bacterial contamination of platelet concentrates: incidence, significance, and prevention. (2001) (81)
Infectious disease testing for blood transfusions. (1995) (80)
Mechanisms of transfusion-associated immunosuppression. (1994) (78)
Incidence and significance of the bacterial contamination of blood components. (2002) (78)
Avoiding Transfusions in Children Undergoing Cardiac Surgery: A Meta-Analysis of Randomized Trials of Aprotinin (2006) (76)
Growth Enhancement of Established Tumors by Allogeneic Blood Transfusion in Experimental Animals and Its Amelioration by Leukodepletion: The Importance of the Timing of the Leukodepletion (1994) (74)
Cytokeratin 18 Is Expressed on the Hepatocyte Plasma Membrane Surface and Interacts with Thrombin-Antithrombin Complexes* (1997) (74)
Current Research on the Immunomodulatory Effect of Allogeneic Blood Transfusion (1996) (71)
The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate (1985) (70)
Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate. (1987) (69)
The age of red blood cells in premature infants (ARIPI) randomized controlled trial: study design. (2009) (68)
Clinical and molecular basis of transfusion-induced immunomodulation: summary of the proceedings of a state-of-the-art conference. (2001) (65)
Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. (1994) (65)
A multicenter pilot‐randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation (2007) (65)
Protecting the Blood Supply From Emerging Pathogens: The Role of Pathogen Inactivation (2005) (63)
Prevalence of factor V Leiden in a Canadian blood donor population. (1996) (63)
The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor (1992) (59)
An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition (1993) (58)
Transfusion-related acute lung injury. (2003) (57)
Molecular basis of inherited human antithrombin deficiency (1992) (55)
Why implement universal leukoreduction? (2008) (55)
Immunosuppressive effects of allogeneic blood transfusions: implications for the patient with a malignancy. (1995) (54)
Addressing the risk of bacterial contamination of platelets within the United States: a history to help illuminate the future (2013) (52)
The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. (1997) (50)
Transient Donath‐Landsteiner Haemolytic Anaemia (1981) (49)
Thrombosis in antithrombin‐III‐deficient persons. Report of a large kindred and literature review (1993) (48)
Passive transfer of peanut hypersensitivity by fresh frozen plasma. (2007) (46)
The Clearance of Thrombin-antithrombin and Related Serpin-enzyme Complexes from the Circulation: Role of Various Hepatocyte Receptors (1999) (46)
Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions. (1995) (45)
The tumor growth-promoting effect of allogeneic blood transfusions. (1995) (45)
Reducing the risk of bacterial contamination of cellular blood components. (2000) (44)
Molecular analysis of glycophorin A and B gene structure and expression in homozygous Miltenberger class V (Mi. V) human erythrocytes. (1989) (44)
In vivo recovery and survival of apheresis and whole blood‐derived platelets: a paired comparison in healthy volunteers (2006) (43)
Transfusion‐related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen (2008) (42)
The spectrum of ABO hemolytic disease of the newborn infant. (1979) (42)
Canadian Red Cross Society symposium on leukodepletion: report of proceedings. (1994) (42)
Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogeneic blood transfusion. (2000) (41)
Novel treatment modalities: new platelet preparations and subsititutes (2001) (41)
Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage (2004) (40)
Hemolytic and pseudo-hemolytic transfusion reactions: an overview of the hemolytic transfusion reactions and the clinical conditions that mimic them. (1994) (40)
Severe hemolytic anemia post-renal transplantation produced by donor anti-D passenger lymphocytes: case report and literature review. (2009) (39)
Assessment of the hemostatic effectiveness of human platelets treated with aminomethyltrimethyl psoralen and UV A light using a rabbit ear bleeding time technique. (1993) (39)
Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin. (1992) (38)
The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. (1980) (37)
Bacterial contamination of blood products and the value of pre-transfusion testing. (1995) (37)
CD200-dependent and nonCD200-dependant pathways of NK cell suppression by human IVIG (2008) (37)
The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor (1984) (35)
Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits. (2003) (35)
Transfusion‐associated bacterial sepsis: the phoenix rises yet again (1994) (35)
Measurement of Markers of Activated Coagulation in Antithrombin III Deficient Subjects (1992) (34)
A multidisciplinary “think tank”: the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute–sponsored 2009 state‐of‐the‐science symposium (2011) (33)
Pseudopolycythemia, pseudothrombocytopenia, and pseudoleukopenia due to overfilling of blood collection vacuum tubes. (1992) (33)
Novel platelet products, substitutes and alternatives. (2001) (33)
Proceedings of a consensus conference: Risk-Based Decision Making for Blood Safety. (2011) (33)
Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy. (1975) (32)
An approach to determine objectively minimum hemoglobin standards for blood donors (1985) (32)
Age‐related changes in factor VII proteolysis in vivo (1996) (32)
IMMUNOGLOBULINS IN WARM-TYPE AUTOIMMUNE HÆMOLYTIC ANÆMIA (1969) (31)
The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits. (1980) (31)
The amount of blood group A substance on platelets is proportional to the amount in the plasma (1982) (30)
Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop (2009) (30)
Substitutes for success (1999) (29)
A proposal for an individual patient data based meta-analysis of randomized controlled trials of allogeneic transfusion and postoperative bacterial infection. (1997) (29)
Defining the heparin-binding domain of antithrombin. (1994) (29)
Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. (1991) (29)
Bacterial contamination of blood products. (2001) (29)
Prostaglandin I2 (prostacyclin). (1980) (28)
In Vivo Clearance of Ternary Complexes of Vitronectin-Thrombin-Antithrombin Is Mediated by Hepatic Heparan Sulfate Proteoglycans* (1998) (27)
Landmark studies that have changed the practice of transfusion medicine (2005) (27)
Plasma Anticoagulant Mechanisms of Heparin, Heparan Sulfate, and Dermatan Sulfate a (1989) (27)
Incorporation of 7-deaza dGTP during the amplification step in the polymerase chain reaction procedure improves subsequent DNA sequencing. (1990) (27)
Alloantibodies and platelet destruction. (1982) (26)
Molecular cloning and expression of rabbit antithrombin III. (1992) (26)
Clinical trial opportunities in Transfusion Medicine: proceedings of a National Heart, Lung, and Blood Institute State-of-the-Science Symposium. (2010) (26)
The amount of blood group A substance on platelets is proportional to the amount in the plasma. (1982) (26)
Extending the horizon for cell-based immunotherapy by understanding the mechanisms of action of photopheresis. (2010) (25)
Immunomodulatory Effects of Blood Transfusion (1999) (25)
transfusion and the available strategies for their prevention Transfusion-related mortality: the ongoing risks of allogeneic blood (2013) (24)
Transfusion-related acute lung injury (2005) (24)
Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. (1982) (24)
Novel platelet products and substitutes. (1998) (24)
The isolation of prothrombin, Factor IX and Factor X from human Factor IX concentrates. (1984) (23)
Regions Flanking Exon 1 Regulate Constitutive Expression of the Human Antithrombin Gene* (1996) (23)
Proceedings of a consensus conference: the screening of blood donors for variant CJD. (2004) (22)
Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa. (1991) (22)
Risks associated with blood transfusion in newborn infants. (1984) (22)
GUTI: a new antigen in the Cromer blood group system (2003) (22)
An increased uptake of prothrombin, antithrombin, and fibrinogen by the rabbit balloon-deendothelialized aorta surface in vivo is maintained until reendothelialization is complete. (1996) (22)
DIAGNOSTIC AMNIOCENTESIS AND FETAL-MATERNAL BLEEDING (1974) (21)
Activation of factor X and prothrombin in antithrombin-III depleted plasma: the effects of heparin. (1981) (21)
Quantitation of red cell membrane associated immunoglobulin in children with Plasmodium falciparum parasitaemia (1983) (21)
Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl. (1990) (21)
Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. (1992) (21)
An Approach to Assigning In Vitro Potency to Unfractionated and Low Molecular Weight Heparins Based on the Inhibition of Prothrombin Activation and Catalysis of Thrombin Inhibition (1988) (21)
A second example of a transfusion‐associated septic reaction associated with Clostridium perfringens (2001) (20)
Transfusion-related immunosuppression (2009) (20)
The role of red blood cell antigens, histocompatibility antigens, and blood transfusions on renal allograft survival. (1989) (20)
o-raffinose cross-linked hemoglobin improves the hemostatic defect associated with anemia and thrombocytopenia in rabbits. (2000) (20)
Platelet transfusions: an historical perspective. (2008) (19)
Universal leucocyte‐depletion of blood components: cell concentrates and plasma (2001) (19)
Catabolism of rabbit prothrombin in rabbits: uptake of prothrombin by the aorta wall before and after a de-endothelializing injury in vivo. (1995) (19)
Activation and Active Site Occupation Alter Conformation in the Region of the First Epidermal Growth Factor-like Domain of Human Factor VII* (2000) (19)
Shortening of the bleeding time in thrombocytopenic rabbits after exposure of jugular vein to high aspirin concentration. (1979) (19)
Expression and purification of recombinant rabbit factor VII. (2000) (18)
A prospective study evaluating the lowering of hemoglobin standards for blood donors (1989) (18)
The molecular pathology of inherited human antithrombin III deficiency. (1989) (18)
Molecular basis of inherited human antithrombin deficiency. (1992) (18)
Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography. (1980) (18)
Clinical use of blood, blood components and blood products. (1979) (17)
Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082. (1992) (17)
Platelet substitutes and novel platelet products (2000) (17)
The low molecular weight heparin Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery (1992) (17)
Red blood cell transfusion strategies. (2001) (17)
Immunodepletion of human plasma factor VIII. (1980) (17)
Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin. (2000) (17)
Envelope glycoprotein of avian hemangioma retrovirus induces a thrombogenic surface on human and bovine endothelial cells (1990) (17)
Transfusion medicine--the coming of age of a new specialty. (1987) (16)
Cytokines in transfusion medicine (1993) (16)
Intracellular events determine the fate of antithrombin Utah. (1995) (16)
Antithrombin III Sudbury: an Ala384----Pro mutation with abnormal thrombin-binding activity and thrombotic diathesis. (1990) (16)
Effect of allogeneic blood transfusion on solid tumor growth and pulmonary metastases in mice (2005) (16)
Molecular Cloning and Cell-Free Expression of Mouse Antithrombin III (1992) (16)
Site‐directed mutagenesis of the P2 residue of human antithrombin (1994) (15)
Looking back in anger: retrospection in the face of a paradigm shift. (1997) (15)
Inhibition of arterial thrombosis and platelet function by nafazatrom. (1982) (15)
INDUCTION OF ANTIIDIOTYPIC ANTIBODIES BY BLOOD TRANSFUSIONS: CHARACTERIZATION OF T CELL ALLOANTIGEN‐SPECIFIC RECEPTORS BY SERA FROM TRANSFUSED MICE (1986) (15)
Complete nucleotide sequence of the cDNA encoding rabbit coagulation factor VII. (1993) (15)
Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity. (2004) (15)
The Procoagulant State of the VX-2 Tumor in Rabbit Lung In Vivo (1999) (14)
Evidence for an alternative mechanism of human platelet secretion involving peripheralization of secretory granules and formation of membrane-associated multivesicular structures. (1987) (14)
An overview of the mechanism of action of antithrombin and its inherited deficiency states (1994) (14)
Partial deletion of an antithrombin III allele in a kindred with a type 1 deficiency. (1992) (14)
Factor VII deficiency caused by a structural variant N57D of the first epidermal growth factor domain. (1998) (14)
Expression in a cell-free system of normal and variant forms of human antithrombin III. Ability to bind heparin and react with alpha-thrombin. (1990) (14)
Neonatal cytomegalovirus infections: the relative role of neonatal blood transfusion and maternal exposure. (1984) (14)
Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin (1995) (14)
The incidence of post-transfusion hepatitis. (1993) (13)
The effect of leukodepletion on allogeneic donor platelet survival and refractoriness in an animal model. (1991) (13)
Amino acid substitutions of the P2 residue of human antithrombin that either enhance or impair function. (1994) (13)
Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. (1997) (13)
Analysis of a pregnancy‐screening and neonatal‐immunization program for hepatitis B in Hamilton, Ontario, Canada, 1977‐1988 (1991) (13)
Transfusion Microbiology: Bacterial contamination in blood and blood components (2008) (12)
Noninfectious adverse effects of blood transfusion in the neonate. (1995) (12)
The thrombogenicity of prothrombin complex concentrates: III. The relationship of in vivo thrombogenicity to the nature of the starting plasma. (1981) (12)
Enhanced prothrombin‐converting activity and factor Xa binding of platelets activated by the alternative complement pathway (1984) (12)
Trinucleotide repeat polymorphism within the human antithrombin gene (AT3): allele frequency data for three population groups. (1994) (12)
Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma. (1990) (12)
Molecular Cloning and Expression of Rabbit Heparin Cofactor II: A Plasma Thrombin Inhibitor Highly Conserved between Species (1994) (12)
HLA-A,B,C and B-lymphocyte alloantigens in insulin-dependent diabetes. (1977) (11)
Association of renal failure with Lewis incompatibility after allogeneic bone marrow transplantation. (1985) (11)
Do surrogate tests improve the safety of the blood supply? (1995) (11)
The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop (2012) (11)
Anti-idiotypic antibodies and suppressor cells in patients receiving pretransplant donor-specific blood transfusions. (1987) (10)
Bacterial contamination of cellular blood products: the Canadian perspective. (2000) (10)
Production in vitro of antibodies directed against alloantigen-specific recognition sites on T cells and on lymphocytotoxic HLA antibodies. (1988) (10)
Effects of methyl prednisolone on platelet adhesion to damaged aorta bleeding time and platelet survival (1976) (10)
Agreement study between two laboratories of immunofluorescence as a confirmatory test for human immunodeficiency virus type 1 antibody screening (1989) (10)
Site‐directed mutagenesis of alanine‐382 of human antithrombin III (1991) (10)
Angiostatin II is the predominant glycoform in pleural effusates of rabbit VX-2 lung tumors. (2002) (10)
Consumption of plasma factor VII in a rabbit model of non-overt disseminated intravascular coagulation. (2002) (10)
Research Ethics Boards: The Protection of Human Subjects (2006) (10)
Letter: HL-A antigens in malignant melanoma. (1974) (10)
ABO haemolytic disease of the new born. (1979) (9)
Immunoglobulins in warm-type autoimmune haemolytic anaemia. (1969) (9)
Molecular genetic basis for the antiidiotypic antibody response associated with successful renal allograft survival in humans. (1991) (8)
CHAPTER 70 – Platelet Substitutes and Novel Methods of Platelet Preservation (2007) (8)
The role of the complement system in hemostasis. (1986) (8)
Metabolism of rabbit plasma-derived factor VII in relation to prothrombin in rabbits. (2001) (8)
Rapid in vivo induction of leukocyte tissue factor mRNA and protein synthesis following low dose endotoxin administration to rabbits. (2001) (8)
The direct binding of human factor VII in plasma to recombinant human tissue factor. (1993) (8)
Role of the ABO, Secretor, and Lewis determinants in the primed lymphocyte test. (1981) (8)
A novel congenital haemostatic defect: combined factor VII and factor XI deficiency (1992) (8)
Arginine-79 in the first epidermal growth factor domain of factor VII is essential for the interaction with tissue factor. (1993) (8)
Immunomodulatory and Proinflammatory Effects of Allogeneic Blood Transfusion (2009) (8)
Tissue antibodies in idiopathic autoimmune haemolytic anaemia. (1971) (7)
Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III. (1984) (7)
Substitution of the “group-and-screen” for the full crossmatch in elective operations (1983) (7)
The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits. (1980) (7)
Blood transfusion : a conceptual approach (1984) (6)
Antithrombin III‐Amiens: A new family with an Arg47 → cys inherited variant of antithrombin iii with impaired heparin cofactor activity (1991) (6)
Uptake of heparin cofactor II and antithrombin into the aorta wall after a deendothelializing injury in vivo: comparison with the behaviors of prothrombin and fibrinogen. (1999) (6)
Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival. (1977) (6)
The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, alpha-thrombin. (1992) (6)
HLA-restricted lymphoproliferative responses to MN blood group determinants (1982) (5)
Molecular analysis of the HLA-D region and the T-cell antigen receptor beta-chain genes in monozygotic twins discordant for rheumatoid arthritis. (1989) (5)
A novel and de novo spontaneous point mutation (Glu271STOP) of the antithrombin gene results in a type I deficiency and thrombophilia (1999) (5)
Transfusion-related issues in Jehovah's Witness patients. (1991) (5)
Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor (1996) (5)
Pioneers and Pathfinders in Transfusion Medicine (2005) (5)
Impact of mutations at the P4 and P5 positions on the reaction of antithrombin with thrombin and elastase. (1997) (5)
Randomized trials in patients with blunt and penetrating trauma. (2006) (4)
Treatment of T. cruzi infected human platelet concentrates with aminomethyltrimethyl psoralen (AMT) and ultraviolet A (UV-A) light: preliminary results. (1996) (4)
The Pathogen Inactivation of Platelets: Studies of the Possible Mechanisms of the Platelet Dysfunction Seen Following Photochemical Treatment. (2006) (4)
Understanding the polymerase chain reaction. (1994) (4)
Letter: Diagnostic amniocentesis and fetal-maternal bleeding. (1974) (4)
Analysis of a Pregnancy-screening and Neonatal-immunization Program for Hepatitis B in Hamilton, Ontario, Canada, 1977–1988 (1992) (4)
Blood component therapy in anaesthetic practice. (1983) (3)
Defining transfusion medicine. (1990) (3)
Bacterial Contamination of Blood Components (2000) (3)
The factor VIII-independent activation of factor X by factors IXa and VII in plasma. (1981) (3)
Approaches to the measurement of the in vivo response to factor VIII concentrate infusion. (1985) (3)
Factor V deficiency and its reversal with gluten restriction. In a patient with celiac disease. (1983) (3)
The in Vivo Evaluation of the Hemostatic Function of Stored Human Platelets (1977) (3)
Antiidiotypic antibodies: production in vitro by EBV-transformed lymphoblastoid cell lines and immunochemical characterization of idiotypic receptors on T-cells. (1989) (3)
Platelet substitutes. (2000) (3)
The blood transfusion effect: characterization of T cell alloantigen-specific receptors by sera from transfused mice. (1987) (3)
Chapter 47 – Bacterial Infections: Bacterial Contamination, Testing, and Post-Transfusion Complications (2007) (3)
Abstract Presentations from the AABB Annual Meeting Philadelphia, PA, October 25‐28, 2014 (2014) (3)
Non-HLA antigens in the primed lymphocyte test (PLT): responses to Lewis determinants. (1981) (3)
Definition of transfusion medicine (2002) (2)
HLA-restricted responses to M and N determinants in the primed lymphocyte test. (1981) (2)
Transfusion Requirements in Critical Care (2017) (2)
A useful restriction analysis for the determination of human antithrombin III variants with mutations from Ala 382 to Ala 384. (1992) (2)
The Antithrombotic Properties of Human Prothrombin Fragment 1.2 in Mice (1990) (2)
Characterization of a highly polymorphic trinucleotide short tandem repeat within the human antithrombin gene. (1994) (2)
The Clinical Relevance and Biological Effects of Leukocytes Present in Cellular Blood Components (1996) (2)
Transfusion‐Related Immunomodulation (TRIM) (2003) (2)
Microheterogeneity of antithrombin III: effect of single amino acid substitutions and relationship with functional abnormalities (1994) (2)
Clinical trial opportunities in hemostasis and thrombosis: NHBLI State‐of‐the‐science symposium (2012) (2)
Comparative catabolism of prothrombin and antithrombin in normal and alloxan-diabetic rabbits. (1997) (2)
Human Factor VIIai(K62E) Is a More Effective Inhibitor of Coagulation Than Wild-Type FVIIai. (2005) (2)
Human Factor VIIai(K62E) Is a More Effective Inhibitor of Coagulation Than Wild-Type FVIIai. (2005) (2)
Rifampicin-induced ImmuneThrombocytopenia (1970) (1)
Thrombosis in Antithrombin-III-deficient Persons (2020) (1)
Clinical Trial Opportunities in Transfusion Medicine: Proceedings of a National Heart, Lung, and Blood Institute State-of the-Science Symposium, 24/4 (October 2010) pp. 259-285 (2011) (1)
CHAPTER 33 – Animal Models (2007) (1)
Blood substitutes--a misnomer, nevertheless a promise. (1982) (1)
Requirement of Factor VIII for the Generation of Xa in a Purified System and in Plasma. (1979) (1)
Platelet refractoriness and alloimmunization are not necessarily synonymous (1994) (1)
270 A Randomized Controlled Trial of Low vs High Hemoglobin Thresholds for Transfusion in Extremely Low-Birth-Weight Infants (2004) (1)
Platelet transfusions. (1979) (1)
Blood Transfusion and Tumor Growth: Studies in Aimal Models (2017) (1)
Panel Discussion: Rationale for replacement therapy for acquired antithrombin III deficiency (1994) (1)
Evidence for independent pathways for the induction of platelet prothrombin-converting activity by thrombin and collagen. (1984) (1)
Placebo tribulations. (2002) (1)
Mini-symposium: The Role of Granulocytes in Transfusion Medicine (1990) (1)
Prostaglandin I2 (prostacycin) (2006) (1)
Molecular Defects in Human Antithrombin III Deficiency (1991) (1)
Michael S. Murphy and Derwood H. Pamphilon, Editors, Practical Transfusion Medicine, Blackwell Science, Oxford UK (2001). (2002) (0)
新鲜冰冻血浆引发花生过敏被动转移 (2008) (0)
Agreement Studybetween TwoLaboratories ofImmunofluorescence as a Confirmatory TestforHumanImmunodeficiency VirusType1 Antibody Screening (1989) (0)
Comparative behavior of prothrombin and fibrinogen at the injured (de-endothelialized) aorta wall of the rabbit in vivo (1994) (0)
Bacterial Contamination of Blood Components (2000) (0)
Role of secretor and lewis antigens in Primed Lymphocyte Test (PLT) (1980) (0)
Efficacy of leukodepletion filters in removing T. cruzi from contaminated blood. (1994) (0)
ENTERAL HYPERALIMENTATION WITH CHEMICALLY DEFINED (2006) (0)
AbstractIn vitro production of antiidiotypic antibodies by EBV-transformed B cell lines from renal transplant recipients (1988) (0)
Chronic Sirolimus Therapy for Lymphangioleiomyomatosis (2014) (0)
The Use of Aprotinin to Reduce Transfusion Requirements in Children Undergoing Cardiac Surgery: A Meta-Analysis. (2004) (0)
of the time of leukodepletion An animal model of allogeneic donor platelet refractoriness: the effect (2011) (0)
Chapter 51 – Transfusion-Related Acute Lung Injury (2007) (0)
Blood transfusion, anesthesia, and host defense. (1990) (0)
A Multicenter, Randomized, Controlled Clinical Pilot Trial of the Feasibility of an Intensive RBC Transfusion Policy for Patients with Acute Leukemia Treated with Induction Chemotherapy or Stem Cell Transplant. (2005) (0)
Scientific Section (2012) (0)
Molecular Cloning and Expression of Rabbit Antithrombin I11 (2003) (0)
A Human Lymphoblastoid Cell Line Secreting Antiidiotypic Antibodies (1989) (0)
adenine) in codon 382 causing impaired serine protease reactivity Antithrombin-III-Hamilton: a gene with a point mutation (guanine to (2011) (0)
BREAST CANCER IN OLD AGE (1970) (0)
activity in plasma by complementary pathways Heparan sulfate and dermatan sulfate inhibit the generation of thrombin (2011) (0)
A Comparison of Two Assays for Platelet Antibodies (1979) (0)
iscritical totheexpression oftheanticoagulant effect ofheparin (1987) (0)
Age-related increases in factor VII proteolysis and tissue factor pathway inhibitor (1996) (0)
Cumulative risks of early red blood cell transfusion (2006) (0)
Clinical Effects of the Immunomodulation Associated with Allogeneic Blood Transfusions (2001) (0)
Association of Renal Failure With Lewis Incompatibility After Allogeneic Bone Marrow Transplantation (1985) (0)
The Hemostatic Response to Arterial Injury in Vivo : Behavior of Prothrombin at the De-Endothelialised Aorta Wall (1995) (0)
Use of Plasma Segments for Estimating Factor VIII Activity in Pools of Fresh Frozen Plasma (1987) (0)
A.M.A. EXTRAORDINARY GENERAL MEETING (1970) (0)
Press Review (1999) (0)
RIFAMPICIN AND THROMBOCYTOPENIA (1970) (0)
Human FVII(K62E) does not exhibit enhanced binding to tissue factor (2008) (0)
Hepatitis B surveillance. (1983) (0)
9 Premature Infants in Need of Transfusion – The Pint Study: A Multicentre International Randomized Trial of Blood Transfusion in ELBW Infants (2004) (0)
An Animal Model Suitable for Predicting In Vivo Behavior of Platelets in Humans: A Tool for New Product Development. (2004) (0)
The Mechanism of Transfusion-Related Immunomodulation Is Related to the Transfusion of Dendritic Cells Expressing the CD200 (OX-2) Tolerance Signal and Alloantigen: Evidence from a Murine Tumor Model. (2004) (0)
Nucleotide sequences of an antiidiotypic antibody from a transplant recipient (2004) (0)
Transfusion‐Associated Septic Reactions (2002) (0)
Frequent association of factor VII defects with other clotting disorders (1992) (0)
The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with , but not cleavage by , cx-thrombin (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Morris A. Blajchman?

Morris A. Blajchman is affiliated with the following schools:

McMaster University

Morris A. Blajchman's Academic­Influence.com Rankings

Why Is Morris A. Blajchman Influential?

Morris A. Blajchman's Published Works

Published Works

What Schools Are Affiliated With Morris A. Blajchman?

Morris A. Blajchman's AcademicInfluence.com Rankings